Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH – Get Free Report)’s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.00. Anthera Pharmaceuticals shares last traded at $0.00, with a volume of 10,000 shares traded.
Anthera Pharmaceuticals Price Performance
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.
Read More
- Five stocks we like better than Anthera Pharmaceuticals
- Why is the Ex-Dividend Date Significant to Investors?
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- Investing in the High PE Growth Stocks
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- Where Do I Find 52-Week Highs and Lows?
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
